Case Report

Maintenance Therapy with Procarbazin and Chlorambucil without Autologous Stem Cell Transplantation as a New Option for Patient with Hodgkin Lymphoma

Mehrdad Payandeht, Masoud Sadeghi1*, Edris Sadeghi3

1Department of Hematology and Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran
2Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
3Department of Nursing, Kermanshah University of Medical Sciences, Kermanshah, Iran

*Corresponding author
Masoud Sadeghi
Email: sadeghi_mbrc@yahoo.com

Abstract: Hodgkin lymphoma (HL) affects patients of all ages, particularly adolescents and young adults between 16-34 years. Patients with HL who relapse following effective front-line therapy are offered salvage second-line chemotherapy regimens followed by high-dose therapy and autologous stem cell transplantation. The aim of this study is a report of a HL patient that treated with maintenance therapy without autologous stem cell transplantation (ASCT) and radiotherapy for four months and had a complete response (CR). In Spring 2014, A 54 year-old women referred to our Clinic. Six years ago was treated with diagnosis of HL stage 2B with cervical and mediastinal involvement and she was treated with 6 courses from ABVD (adriamycin, belomycin, vinblastine and dacarbazine) regimen. During last six months ago with chief complaints of abdominal pain, weight loss and fever referred to Hematology Clinic. In restating, after bone marrow biopsy and whole body CT scan, both lungs and right side of liver were involved. We selected second-line chemotherapy individualized, second-line chemotherapy of ICE (ifosfamide, carboplatin, etoposide) regimen. The patient was selected for ASCT but she denied of this recommendation. We decide that continue maintenance therapy of procarbazin and chlorambucil for this patient. Final message of this case is that maintenance therapy can be considered in HL relapse cases that not referred for another new decision (such as ASCT), either by patient or manager team, and this regimen can be a new option for patients with HL.

Keywords: Autologous Stem Cell Transplantation, Hodgkin Lymphoma (HL), Maintenance Therapy.

INTRODUCTION

Hodgkin lymphoma (HL) affects patients of all ages, particularly adolescents and young adults (ages 16–34) [1]. Relapses occur in 20-30% of patients with HL [2]. Patients with HL who relapse following effective front-line therapy are offered salvage second-line chemotherapy regimens followed by high-dose therapy and autologous stem cell transplantation (ASCT) [3]. More than 70% of patients can be cured with the current strategies based on chemotherapy, with or without radiotherapy. One-third of the cases finally relapses and need salvage regimens that are usually consolidated with high-dose chemotherapy and ASCT [4].

Herein, we reported a patient with HL that treated with maintenance therapy without ASCT and radiotherapy for four months and had a complete response (CR).

CASE REPORT

Spring 2014, A 54 year-old women referred to our Clinic. Six years ago was treated with diagnosis of Hodgkin Lymphoma (HL) stage 2B with cervical and mediastinal involvement and she was treated with 6 courses from ABVD (adriamycin, belomycin, vinblastine and dacarbazine) regimen. During last six years in close follow up be without symptom and all laboratory and imaging was normal. During last six months ago with chief complaints of abdominal pain, weight loss and fever referred to Hematology Clinic. In further evaluation multiple well defined masses detected in lung CT scan and right liver lobe in CT scan (Fig. 1). Suspected relapse should be confirmed with liver CT guided biopsy, and in complimentary immunohistochemistry (IHC), CD30 and CD15 both were positive. This patient had long disease-free intervals but with unfavorable features (B-symptom, and parenchyma involvement). In restating, after bone marrow biopsy and whole body CT scan, both lungs and right side of liver were involved. We selected second-line chemotherapy individualized, second-line chemotherapy of ICE (ifosfamide, carboplatin, etoposide) regimen as an appropriate treatment for this patient with relapsed disease, with the length of initial remission. After four courses (time between course of chemotherapy in ICE regimen be 2 weeks) for 2 months, all lesions of lung and liver...
resolved (Fig. 2) and patient was selected for ASCT but she denied of this recommendation. We decide that continue maintenance therapy of procarbazin and chlorambucil for this patient. At now after four months of this policy she is alive and all lesions also subside and achieved a CR.

Fig. 1: CT scan of abdominal shows a well define hypo-dense mass from liver before treatment in the beginning of disease

Fig. 2: CT scan of abdominal of patient after 4 courses of chemotherapy that shows resolution of live lesion

DISCUSSION
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for HL include the clinical management of classical HL and lymphocyte-predominant HL (LPHL) [5]. Historically, radiotherapy (RT) to all involved lymph node volumes was the first available curative treatment for children and adults [1]. The standard treatment for relapsed or refractory (rel/ref) HL is high-dose chemoradiotherapy followed by ASCT [6-9] or a salvage regimen (ICE) followed by ASCT [10]. The ICE regimen is an effective, dose-intense, short-course cytoreductive regimen capable of mobilizing peripheral blood progenitor cells (PBPCs) with minimal extramedullary toxicity [11].

Approximately 80% of patients with advanced stage HL achieve a CR when treated with ABVD, [12,13] the current gold-standard up-front HL therapy in the United States, or ABVD/MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) hybrid therapy [13]. Druker BJ et al. [14] concluded that chlorambucil, vinblastine, procarbazine,
and prednisone (ChlVPP) appears as effective as MOPP chemotherapy for Hodgkin's disease in comparable presentations but is a less toxic regimen. ABVD continues to be the standard of care for patients with advanced stage HL, although escalated BEACOPP (bleomycin, etopooside, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) has improved survival in one randomized controlled trial (RCT) [15].

A study [16] reported that vinorelbine, paclitaxel, etoposide, and cisplatin (VTEPA) is a promising regimen for HL patients in whom previous lines of therapy have failed.

Another study in 2014 [17] for four patients showed that all patients received the ABVD regimen followed by salvage treatment with ICE regimen. After relapse, patients were subsequently treated with brentuximab as maintenance therapy. Only 1 of the 4 patients achieved a CR after nine cycles, 2 of the other 3 had progressive disease after partial response, and in the fourth patient disease progressed immediately after brentuximab treatment.

In our study, the patient was treated with ABVD (first-line chemotherapy) and then ICE (second-line chemotherapy) without radiotherapy. The important thing is that in our patient without ASCT and with maintenance therapy (procarbazine and chlorambucil), her lesions in liver and lung was reduced and had a CR. This treatment is a new treatment about HL.

CONCLUSION

Final message of this case is that maintenance therapy can be considered in HL relapse cases that not referred for another new decision (such as ASCT), either by patient or manager team, and this regimen can be a new option for patients with HL.

REFERENCES